Advertisement

Angiogenesis and Lung Cancer

  • Wenyin Shi
  • Dietmar W. Siemann
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Lung cancer is one of the most frequent causes of cancer deaths worldwide. Current treatment regimens with conventional anticancer therapies offer only a limited survival benefit. There clearly exists a need for the development of new therapeutic strategies. Recent evidence suggests that angiogenesis is critical to lung cancer progression and related to poor prognosis. Consequently tumor angiogenesis, a process that features an imbalance between pro and anti-angiogenic mediators, is being targeted by novel therapies in the treatment of lung cancer. A variety of therapeutic approaches and agents have been developed to compromise the growth and/or function of tumor vasculature. In October 2006, bevacizumab was the first antiangiogenic agent approved by the US Food and Drug Administration for the treatment of advanced, nonsquamous, nonsmall cell lung cancer in combination with platinum-based chemotherapy. Other antiangiogenic agents are actively being evaluated in pre-clinical and clinical settings.

Keywords

Vascular Endothelial Growth Factor NSCLC Patient Vascular Endothelial Growth Factor Expression Advanced NSCLC Vascular Endothelial Growth Factor Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abdelrahim M, Konduri S et al (2010) Angiogenesis: an update and potential drug approaches (review). Int J Oncol 36(1):5–18PubMedGoogle Scholar
  2. Altorki NK, Keresztes RS et al (2003) Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early stage non-small-cell lung cancer. J Clin Oncol 21(14):2645–2650PubMedCrossRefGoogle Scholar
  3. Altorki N, Lane ME et al (2010) Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 28(19):3131–3137PubMedCrossRefGoogle Scholar
  4. Anagnostou VK, Tiniakos DG et al (2011) Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients. Virchows Arch 458(3):331–340PubMedCrossRefGoogle Scholar
  5. Anderson H, Yap JT et al (2003) Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 89(2):262–267PubMedCrossRefGoogle Scholar
  6. Angeletti CA, Lucchi M et al (1996) Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 78(3):409–415PubMedCrossRefGoogle Scholar
  7. Apolinario RM, van der Valk P et al (1997) Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15(6):2456–2466PubMedGoogle Scholar
  8. Bach-Gansmo T, Bogsrud TV et al (2008) Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692. Clin Physiol Funct Imaging 28(4):235–239PubMedCrossRefGoogle Scholar
  9. Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4(3):141–148PubMedCrossRefGoogle Scholar
  10. Baguley BC, McKeage MJ (2010) ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. Future Oncol 6(10):1537–1543PubMedCrossRefGoogle Scholar
  11. Baguley BC, Siemann DW (2010) Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opin Investig Drugs 19(11):1413–1425PubMedCrossRefGoogle Scholar
  12. Batchelor TT, Sorensen AG et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83–95PubMedCrossRefGoogle Scholar
  13. Beadsmoore CJ, Screaton NJ (2003) Classification, staging and prognosis of lung cancer. Eur J Radiol 45(1):8–17PubMedCrossRefGoogle Scholar
  14. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410PubMedCrossRefGoogle Scholar
  15. Bernaards CHP, Chen D et al (2010) Circulating VEGF as a biomarker for bevacizumab based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. J Clin Oncol 28(suppl):10519Google Scholar
  16. Bissett D, O’Byrne KJ et al (2005) Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23(4):842–849PubMedCrossRefGoogle Scholar
  17. Bonnesen B, Pappot H et al (2009) Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 66(3):314–318PubMedCrossRefGoogle Scholar
  18. Bono AV, Celato N et al (2002) Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5(2):123–127PubMedCrossRefGoogle Scholar
  19. Botrel TE, Clark O et al (2011) Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis. Lung Cancer (Epub ahead of print)Google Scholar
  20. Brattstrom D, Bergqvist M et al (1998) Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small-cell lung cancer patients. Anticancer Res 18(2A):1123–1127PubMedGoogle Scholar
  21. Brooks PC, Montgomery AM et al (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79(7):1157–1164PubMedCrossRefGoogle Scholar
  22. Caron C, Spring K et al (2009) Non-redundant roles of the Gab1 and Gab2 scaffolding adapters in VEGF-mediated signalling, migration, and survival of endothelial cells. Cell Signal 21(6):943–953PubMedCrossRefGoogle Scholar
  23. Carrillo de Santa Pau E, Arias FC et al (2009) Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with non-small-cell lung cancer. Cancer 115(8):1701–1712PubMedCrossRefGoogle Scholar
  24. Carrillo-de Santa Pau E, Carrillo Arias F et al (2010) Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 28(4):393–398PubMedGoogle Scholar
  25. Chandrachud LM, Pendleton N et al (1997) Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer 76(10):1367–1375PubMedCrossRefGoogle Scholar
  26. Chen Y, Liang B et al (2010) Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer. Diagn Cytopathol (Epub ahead of print)Google Scholar
  27. Ching LM, Zwain S et al (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90(4):906–910PubMedCrossRefGoogle Scholar
  28. Chouaib S, Kieda C et al (2010) Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol 30(6):529–545PubMedCrossRefGoogle Scholar
  29. Ciardiello F, Caputo R et al (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9(4):1546–1556PubMedGoogle Scholar
  30. Clement-Duchene C, Wakelee H (2010) Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review. J Thorac Oncol 5(1):129–139PubMedGoogle Scholar
  31. Collingridge DR, Carroll VA et al (2002) The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62(20):5912–5919PubMedGoogle Scholar
  32. Comis RL (2003) A brief history of the research and treatment of lung cancer from 1970 to 2003. Int J Clin Oncol 8(4):230–233PubMedCrossRefGoogle Scholar
  33. Connolly DT, Olander JV et al (1989) Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264(33):20017–20024PubMedGoogle Scholar
  34. D’Amato RJ, Loughnan MS et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91(9):4082–4085PubMedCrossRefGoogle Scholar
  35. Dalaveris E, Kerenidi T et al (2009) VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer 64(2):219–225PubMedCrossRefGoogle Scholar
  36. Dannenberg AJ, Altorki NK et al (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2(9):544–551PubMedCrossRefGoogle Scholar
  37. de Boer RH, Arrieta O et al (2011) Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial. J Clin Oncol (Epub ahead of print)Google Scholar
  38. Decaussin M, Sartelet H et al (1999) Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival. J Pathol 188(4):369–377PubMedCrossRefGoogle Scholar
  39. Denekamp J (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9(3):267–282PubMedCrossRefGoogle Scholar
  40. Deshpande N, Pysz MA et al (2010) Molecular ultrasound assessment of tumor angiogenesis. Angiogenesis 13(2):175–188PubMedCrossRefGoogle Scholar
  41. Dickinson AJ, Fox SB et al (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74(6):762–766PubMedCrossRefGoogle Scholar
  42. Dowlati A, Subbiah S et al (2007) Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer 56(3):377–381PubMedCrossRefGoogle Scholar
  43. Dowlati A, Gray R et al (2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab–an Eastern Cooperative Oncology Group Study. Clin Cancer Res 14(5):1407–1412PubMedCrossRefGoogle Scholar
  44. Drevs J (2003) Soluble markers for the detection of hypoxia under antiangiogenic treatment. Anticancer Res 23(2A):1159–1161PubMedGoogle Scholar
  45. Dudek A, Gupta K et al (2010) Tumor angiogenesis. J Oncol (Epub ahead of print)Google Scholar
  46. Dudek AZ, Lesniewski-Kmak K et al (2009) Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small-cell lung cancer. J Thorac Oncol 4(8):969–975PubMedCrossRefGoogle Scholar
  47. Edwards BK, Brown ML et al (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427PubMedCrossRefGoogle Scholar
  48. Eliceiri BP, Cheresh DA (1999) The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest 103(9):1227–1230PubMedCrossRefGoogle Scholar
  49. Erdi YE, Macapinlac H et al (2000) Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27(7):861–866PubMedCrossRefGoogle Scholar
  50. Eriksson R, Persson HW et al (1991) Evaluation of Doppler ultrasound for blood perfusion measurements. Ultrasound Med Biol 17(5):445–452PubMedCrossRefGoogle Scholar
  51. Escudier B, Eisen T et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134PubMedCrossRefGoogle Scholar
  52. Fabbro D, Manley PW (2001) Su-6668. SUGEN. Curr Opin Investig Drugs 2(8):1142–1148PubMedGoogle Scholar
  53. Feng Y, Wang W et al (2010) Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small-cell lung cancer. Anat Rec (Hoboken) 293(5):802–812CrossRefGoogle Scholar
  54. Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29(6 Suppl 16):10–14PubMedGoogle Scholar
  55. Ferrara N, Gerber HP et al (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676PubMedCrossRefGoogle Scholar
  56. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285(21):1182–1186PubMedCrossRefGoogle Scholar
  57. Folkman J (1975) Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 82(1):96–100PubMedCrossRefGoogle Scholar
  58. Folkman J (1990a) Endothelial cells and angiogenic growth factors in cancer growth and metastasis introduction. Cancer Metastasis Rev 9(3):171–174PubMedCrossRefGoogle Scholar
  59. Folkman J (1990b) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1):4–6PubMedCrossRefGoogle Scholar
  60. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27–31PubMedCrossRefGoogle Scholar
  61. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15–18PubMedGoogle Scholar
  62. Fontanini G, Bigini D et al (1995) Microvessel count predicts metastatic disease and survival in non-small-cell lung cancer. J Pathol 177(1):57–63PubMedCrossRefGoogle Scholar
  63. Fontanini G, Faviana P et al (2002) A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small-cell-lung carcinoma. Br J Cancer 86(4):558–563PubMedCrossRefGoogle Scholar
  64. Gadducci A, Viacava P et al (2003) Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res 23(1B):549–556PubMedGoogle Scholar
  65. Galbraith SM, Chaplin DJ et al (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21(1A):93–102PubMedGoogle Scholar
  66. Galbraith SM, Lodge MA et al (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis. NMR Biomed 15(2):132–142PubMedCrossRefGoogle Scholar
  67. Galbraith SM, Maxwell RJ et al (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21(15):2831–2842PubMedCrossRefGoogle Scholar
  68. Galustian C, Dalgleish A (2009) Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 10(1):125–133PubMedCrossRefGoogle Scholar
  69. Gauler TC, BB Meric JB et al (2007) Phase II open-label study to investigate efficacy and safety of PTK787/ZK222584 orally administered once daily or twice daily at 1, 250 mg as second line monotherapy in patients with stage IIIB/V NSCLC. J Clin Oncol 25:7541Google Scholar
  70. Gerber HP, Dixit V et al (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273(21):13313–13316PubMedCrossRefGoogle Scholar
  71. Gialeli C, Theocharis AD et al (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278(1):16–27PubMedCrossRefGoogle Scholar
  72. Gingras D, Boivin D et al (2003) Neovastat–a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14(2):91–96PubMedCrossRefGoogle Scholar
  73. Goh V, Halligan S et al (2009) Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol 19(1):79–89PubMedCrossRefGoogle Scholar
  74. Gordon MS, Mendelson DS et al (2010) Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer 126(8):1777–1787PubMedGoogle Scholar
  75. Goss GD, Arnold A et al (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28(1):49–55PubMedCrossRefGoogle Scholar
  76. Guddo F, Fontanini G et al (1999) The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small-cell lung cancer progression. Hum Pathol 30(7):788–794PubMedCrossRefGoogle Scholar
  77. Guidi AJ, Fischer L et al (1994) Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86(8):614–619PubMedCrossRefGoogle Scholar
  78. Guo X, Chen Y et al (2009) Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small-cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 41(3):217–222CrossRefGoogle Scholar
  79. Hasan J, Byers R et al (2002) Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86(10):1566–1577PubMedCrossRefGoogle Scholar
  80. Haubner R, Beer AJ et al (2010) Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging 37(Suppl 1):S86–103PubMedCrossRefGoogle Scholar
  81. Hawighorst H, Libicher M et al (1999) Evaluation of angiogenesis and perfusion of bone marrow lesions: Role of semiquantitative and quantitative dynamic MRI. J Magn Reson Imaging 10(3):286–294PubMedCrossRefGoogle Scholar
  82. Heng DY, Kollmannsberger C (2010) Sunitinib. Recent Results Cancer Res 184:71–82PubMedCrossRefGoogle Scholar
  83. Herbst RS, Hess KR et al (2002a) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20(18):3792–3803PubMedCrossRefGoogle Scholar
  84. Herbst RS, Madden TL et al (2002b) Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20(22):4440–4447PubMedCrossRefGoogle Scholar
  85. Herbst RS, Sun Y et al (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11(7):619–626PubMedCrossRefGoogle Scholar
  86. Herrmann E, Bogemann M et al (2007) The role of the endothelin axis and microvessel density in bladder cancer—correlation with tumor angiogenesis and clinical prognosis. Oncol Rep 18(1):133–138PubMedGoogle Scholar
  87. Heymach JV, Paz-Ares L et al (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407–5415PubMedCrossRefGoogle Scholar
  88. Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93(3):178–193PubMedCrossRefGoogle Scholar
  89. Hlatky L, Hahnfeldt P et al (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 94(12):883–893PubMedCrossRefGoogle Scholar
  90. Hoekstra CJ, Stroobants SG et al (2002) Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 8(7):2109–2115PubMedGoogle Scholar
  91. Holash J, Maisonpierre PC et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422):1994–1998PubMedCrossRefGoogle Scholar
  92. Holden SN, Eckhardt SG et al (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16(8):1391–1397PubMedCrossRefGoogle Scholar
  93. Horn L, Dahlberg SE et al (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27(35):6006–6011PubMedCrossRefGoogle Scholar
  94. Hu-Lowe DD, Zou HY et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14(22):7272–7283PubMedCrossRefGoogle Scholar
  95. Hurwitz H, Fehrenbacher L et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRefGoogle Scholar
  96. Hurwitz H, Douglas PS, Middleton JP et al (2010) Analysis of early hypertension and clinical outcome with bevacizumab. J Clin Oncol 28(suppl):3039Google Scholar
  97. Jain RK, Duda DG et al (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6(6):327–338PubMedCrossRefGoogle Scholar
  98. Jalal S, Bedano P et al (2010) Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol 5(12):2008–2011PubMedCrossRefGoogle Scholar
  99. Jayson GC, Zweit J et al (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94(19):1484–1493PubMedCrossRefGoogle Scholar
  100. Jazieh AR, Komrokji R et al (2009) Phase II Trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer. Cancer Invest 27(9):923–926CrossRefGoogle Scholar
  101. Jemal A, Siegel R et al (2010) Cancer statistics (2010). CA Cancer J Clin 60(5):277–300PubMedCrossRefGoogle Scholar
  102. Johnson DH, Fehrenbacher L et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191PubMedCrossRefGoogle Scholar
  103. Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11(12):1172–1183PubMedCrossRefGoogle Scholar
  104. Kalmadi S, Davis M et al (2007) Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs 25(3):211–216PubMedCrossRefGoogle Scholar
  105. Kanthou C, Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99(6):2060–2069PubMedCrossRefGoogle Scholar
  106. Keith RL, Miller YE et al (2000) Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 6(5):1616–1625PubMedGoogle Scholar
  107. Kelly RJ, Rixe O (2010) Axitinib (AG-013736). Recent Results Cancer Res 184:33–44PubMedCrossRefGoogle Scholar
  108. Kepka L, Sprawka A et al (2009) Combination of radiotherapy and chemotherapy in locally advanced NSCLC. Expert Rev Anticancer Ther 9(10):1389–1403PubMedCrossRefGoogle Scholar
  109. Kerbel RS (2000) Tumor angiogenesis: Past, present and the near future. Carcinogenesis 21(3):505–515PubMedCrossRefGoogle Scholar
  110. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049PubMedCrossRefGoogle Scholar
  111. Khan AW, Dhillon AP et al (2002) Prognostic significance of intratumoural microvessel density (IMD) in resected pancreatic and ampullary cancers to standard histopathological variables and survival. Eur J Surg Oncol 28(6):637–644PubMedCrossRefGoogle Scholar
  112. Kim KJ, Li B et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844PubMedCrossRefGoogle Scholar
  113. Kostakoglu L, Goldsmith SJ (2003) 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 44(2):224–239PubMedGoogle Scholar
  114. Koukourakis MI, Giatromanolaki A et al (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small-cell lung cancer. Cancer Res 60(11):3088–3095PubMedGoogle Scholar
  115. Lacy MQ, Tefferi A (2011) Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma 52(4):560–566PubMedCrossRefGoogle Scholar
  116. Landuyt W, Theys J et al (2001) Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes. Cancer Invest 19(1):35–40PubMedCrossRefGoogle Scholar
  117. Laurie SA, Gauthier I et al (2008) Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 26(11):1871–1878PubMedCrossRefGoogle Scholar
  118. Lee JS, Kim HS et al (2002) Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol 85(3):469–475PubMedCrossRefGoogle Scholar
  119. Lee SM, Rudd R et al (2009) Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27(31):5248–5254PubMedCrossRefGoogle Scholar
  120. Leighl NB, Paz-Ares L et al (2005) Randomized phase III study of matrix metalloproteinase inhibitor BMS–275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18. J Clin Oncol 23(12):2831–2839PubMedCrossRefGoogle Scholar
  121. Leighl NB, Raez LE et al (2010) A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 5(7):1054–1059PubMedGoogle Scholar
  122. Leong-Poi H, Christiansen J et al (2003) Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation 107(3):455–460PubMedCrossRefGoogle Scholar
  123. Levitt NC, Eskens FA et al (2001) Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7(7):1912–1922PubMedGoogle Scholar
  124. Li X, Liu X et al (2003) Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 23(3B):2481–2487PubMedGoogle Scholar
  125. Li KL, Wilmes LJ et al (2005) Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging 22(4):511–519PubMedCrossRefGoogle Scholar
  126. Liekens S, De Clercq E et al (2001) Angiogenesis: Regulators and clinical applications. Biochem Pharmacol 61(3):253–270PubMedCrossRefGoogle Scholar
  127. Lin Q, Li M et al (2010) Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small-cell lung cancer. Jpn J Clin Oncol 40(7):670–676PubMedCrossRefGoogle Scholar
  128. Ling Y, Yang Y et al (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361(1):79–84PubMedCrossRefGoogle Scholar
  129. Lockhart AC, Rothenberg ML et al (2010) Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28(2):207–214PubMedCrossRefGoogle Scholar
  130. Lopez-Campos JL, Sanchez Silva R et al (2011) Overexpression of Aquaporin-1 in lung adenocarcinomas and pleural mesotheliomas. Histol Histopathol 26(4):451–459PubMedGoogle Scholar
  131. Loupakis F, Falcone A et al (2007) Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 25(13):1816–1818PubMedCrossRefGoogle Scholar
  132. Lozonschi L, Sunamura M et al (1999) Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59(6):1252–1258PubMedGoogle Scholar
  133. Lu JF, Bruno R et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62(5):779–786PubMedCrossRefGoogle Scholar
  134. Lu C, Lee JJ et al (2010) Chemoradiotherapy with or without AE-941 in stage III non-small-cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 102(12):859–865PubMedCrossRefGoogle Scholar
  135. Lucchi M, Mussi A et al (2002) Small-cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 21(6):1105–1110PubMedCrossRefGoogle Scholar
  136. Macchiarini P, Fontanini G et al (1992) Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340(8812):145–146PubMedCrossRefGoogle Scholar
  137. Macluskey M, Baillie R et al (2000) High levels of apoptosis are associated with improved survival in non-small cell lung cancer. Anticancer Res 20(3B):2123–2128PubMedGoogle Scholar
  138. Mahzouni P, Mohammadizadeh F et al (2010) Determining the relationship between “microvessel density and different grades of astrocytoma based on immunohistochemistry for factor VIII-related antigen (von Willebrand factor) expression in tumor microvessels. Indian J Pathol Microbiol 53(4):605–610PubMedCrossRefGoogle Scholar
  139. Massi D, Franchi A et al (2002) Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma. A quantitative morphologic analysis. Virchows Arch 440(1):22–28PubMedCrossRefGoogle Scholar
  140. Matsuyama W, Hashiguchi T et al (2000) Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 118(4):948–951PubMedCrossRefGoogle Scholar
  141. Mattern J, Koomagi R et al (1996) Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73(7):931–934PubMedCrossRefGoogle Scholar
  142. McCulloch P, Choy A et al (1995) Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346(8986):1334–1335PubMedCrossRefGoogle Scholar
  143. McKeage MJ, Reck M et al (2009) Phase II study of ASA404 (vadimezan, 5, 6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small-cell lung cancer. Lung Cancer 65(2):192–197PubMedCrossRefGoogle Scholar
  144. Medetoglu B, Gunluoglu MZ et al (2010) Tumor angiogenesis in predicting the survival of patients with stage I lung cancer. J Thorac Cardiovasc Surg 140(5):996–1000PubMedCrossRefGoogle Scholar
  145. Miettinen M (1993) Immunohistochemistry in tumour diagnosis. Ann Med 25(3):221–233PubMedCrossRefGoogle Scholar
  146. Mihaylova Z, Ludovini V et al (2007) Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small-cell lung cancer patients. J BUON 12(1):105–111PubMedGoogle Scholar
  147. Miles KA (2003) Perfusion CT for the assessment of tumour vascularity: Which protocol? Br J Radiol 76(Spec No 1):S36–42PubMedCrossRefGoogle Scholar
  148. Miles KA, Charnsangavej C et al (2000) Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7(10):840–850PubMedCrossRefGoogle Scholar
  149. Miller VA, O’CP, Soh C et al (2009) A randomized double-blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completeion of chemotherapy with B for first-line tratment of locally advanced, recurrent, or metastastic non-small-cell lung cancer (NSCLC). J Clin Oncol 27(18s)Google Scholar
  150. Miller AA, Case D et al (2006) Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small-cell lung cancer. J Thorac Oncol 1(8):832–836PubMedCrossRefGoogle Scholar
  151. Miller AA, Case D et al (2007) Phase I study of lenalidomide in solid tumors. J Thorac Oncol 2(5):445–449PubMedCrossRefGoogle Scholar
  152. Minardi D, Lucarini G et al (2008) Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol 21(2):447–455PubMedGoogle Scholar
  153. Moore BB, Arenberg DA et al (1998) Tumor angiogenesis is regulated by CXC chemokines. J Lab Clin Med 132(2):97–103PubMedCrossRefGoogle Scholar
  154. Mountain CF (2000) The international system for staging lung cancer. Semin Surg Oncol 18(2):106–115PubMedCrossRefGoogle Scholar
  155. Mountain CF, Hermes KE (2003) Surgical treatment of lung cancer. Past and present. Methods Mol Med 75:453–487PubMedGoogle Scholar
  156. Mross K, Stefanic M et al (2010) Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16(1):311–319PubMedCrossRefGoogle Scholar
  157. Mutter R, Lu B et al (2009) A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small-cell lung cancer. Clin Cancer Res 15(6):2158–2165PubMedCrossRefGoogle Scholar
  158. Natale RB, Thongprasert S et al (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol (Epub ahead of print)Google Scholar
  159. Natale RB, Bodkin D et al (2009) Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 27(15):2523–2529PubMedCrossRefGoogle Scholar
  160. Ng QS, Goh V et al (2007a) Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 67(5):1375–1380PubMedCrossRefGoogle Scholar
  161. Ng QS, Goh V et al (2007b) Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys 67(2):417–424PubMedCrossRefGoogle Scholar
  162. Ng CS, Kodama Y et al (2009) Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. J Comput Assist Tomogr 33(3):460–465PubMedCrossRefGoogle Scholar
  163. Nilsson F, Kosmehl H et al (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61(2):711–716PubMedGoogle Scholar
  164. Novello S, Scagliotti GV et al (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small-cell lung cancer. Br J Cancer 101(9):1543–1548PubMedCrossRefGoogle Scholar
  165. O’Reilly MS (1997) Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 79:273–294PubMedGoogle Scholar
  166. O’Reilly MS, Holmgren L et al (1994) Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59:471–482PubMedCrossRefGoogle Scholar
  167. O’Reilly MS, Boehm T et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–285PubMedCrossRefGoogle Scholar
  168. Ohta Y, Endo Y et al (1996) Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2(8):1411–1416PubMedGoogle Scholar
  169. Ohta Y, Ohta N et al (2002) Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side. Chest 121(5):1624–1627PubMedCrossRefGoogle Scholar
  170. Oshika Y, Nakamura M et al (2000) Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small-cell lung cancer (NSCLC). Eur J Cancer 36(18):2390–2396PubMedCrossRefGoogle Scholar
  171. Osterlund P, Soveri LM et al (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104(4):599–604PubMedCrossRefGoogle Scholar
  172. Paku S (1998) Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 4(1):62–75PubMedCrossRefGoogle Scholar
  173. Papamichael D (2001) Prognostic role of angiogenesis in colorectal cancer. Anticancer Res 21(6B):4349–4353PubMedGoogle Scholar
  174. Papapetropoulos A, Garcia-Cardena G et al (1999) Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79(2):213–223PubMedGoogle Scholar
  175. Park MS, Klotz E et al (2009) Perfusion CT: Noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 250(1):110–117PubMedCrossRefGoogle Scholar
  176. Pastorino U, Andreola S et al (1997) Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 15(8):2858–2865PubMedGoogle Scholar
  177. Patel JD, Hensing TA et al (2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell-lung cancer. J Clin Oncol 27(20):3284–3289PubMedCrossRefGoogle Scholar
  178. Pathak AP, Penet MF et al (2010) MR molecular imaging of tumor vasculature and vascular targets. Adv Genet 69:1–30PubMedCrossRefGoogle Scholar
  179. Pavco PA, Bouhana KS et al (2000) Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6(5):2094–2103PubMedGoogle Scholar
  180. Pezzella F, Pastorino U et al (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151(5):1417–1423PubMedGoogle Scholar
  181. Philpott M, Joseph WR et al (1997) Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5, 6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 76(12):1586–1591PubMedCrossRefGoogle Scholar
  182. Polverino A, Coxon A et al (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66(17):8715–8721PubMedCrossRefGoogle Scholar
  183. Posther KE, Harpole DH Jr (2006) The surgical management of lung cancer. Cancer Invest 24(1):56–67PubMedCrossRefGoogle Scholar
  184. Poulaki V (2002) BMS-275291. Bristol-Myers Squibb. Curr Opin Investig Drugs 3(3):500–504PubMedGoogle Scholar
  185. Purdie TG, Henderson E et al (2001) Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumour. Phys Med Biol 46(12):3161–3175PubMedCrossRefGoogle Scholar
  186. Rades D, Setter C et al (2010) Fibroblast growth factor 2-A predictor of outcome for patients irradiated for stage ii-iii non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (Epub ahead of print)Google Scholar
  187. Rades D, Setter C et al (2010) Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC). Strahlenther Onkol 186(6):307–314PubMedCrossRefGoogle Scholar
  188. Reck M, Kaiser R et al (2011) A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann OncolGoogle Scholar
  189. Reck M, von Pawel J et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8):1227–1234PubMedCrossRefGoogle Scholar
  190. Reckamp K, Gitlitz B et al (2011) Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer 117(4):809–818PubMedCrossRefGoogle Scholar
  191. Riely GJ, Miller VA (2007) Vascular endothelial growth factor trap in non-small-cell lung cancer. Clin Cancer Res 13(15 Pt 2):s4623–4627PubMedCrossRefGoogle Scholar
  192. Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 9(6):739–745PubMedCrossRefGoogle Scholar
  193. Rini BI, Halabi S et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143PubMedCrossRefGoogle Scholar
  194. Risau W (1997) Mechanisms of angiogenesis. Nature 386(6626):671–674PubMedCrossRefGoogle Scholar
  195. Roca C, Adams RH (2007) Regulation of vascular morphogenesis by Notch signaling. Genes Dev 21(20):2511–2524PubMedCrossRefGoogle Scholar
  196. Roodink I, Leenders WP (2010) Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Lett 299(1):1–10PubMedCrossRefGoogle Scholar
  197. Rosen LS, Kurzrock R et al (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25(17):2369–2376PubMedCrossRefGoogle Scholar
  198. Rugo HS, Herbst RS et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23(24):5474–5483PubMedCrossRefGoogle Scholar
  199. Ruotsalainen T, Joensuu H et al (2002) High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small-cell-lung cancer. Cancer Epidemiol Biomarkers Prev 11(11):1492–1495PubMedGoogle Scholar
  200. Rustin GJ, Shreeves G et al (2010) A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 102(9):1355–1360PubMedCrossRefGoogle Scholar
  201. Salven P, Ruotsalainen T et al (1998) High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79(2):144–146PubMedCrossRefGoogle Scholar
  202. Sandler A, Gray R et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550PubMedCrossRefGoogle Scholar
  203. Scagliotti G, Novello S et al (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28(11):1835–1842PubMedCrossRefGoogle Scholar
  204. Schiller JH, Larson T et al (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from a phase II study. J Clin Oncol 27(23):3836–3841PubMedCrossRefGoogle Scholar
  205. Schneider BJ, Kalemkerian GP et al (2008a) Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol 3(12):1454–1459PubMedCrossRefGoogle Scholar
  206. Schneider BP, Wang M et al (2008b) Association of vascular endothelial growth factor, vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672–4678PubMedCrossRefGoogle Scholar
  207. Schnell O, Krebs B et al (2009) Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 11(6):861–870PubMedCrossRefGoogle Scholar
  208. Schultheis AM, Lurje G et al (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14(22):7554–7563PubMedCrossRefGoogle Scholar
  209. Schwartz JD, Rowinsky EK et al (2010) Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer 116(4 Suppl):1027–1032PubMedCrossRefGoogle Scholar
  210. Scott EN, Meinhardt G et al (2007) Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs 16(3):367–379PubMedCrossRefGoogle Scholar
  211. Senger DR, Perruzzi CA et al (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46(11):5629–5632PubMedGoogle Scholar
  212. Seto T, Higashiyama M et al (2006) Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53(1):91–96PubMedCrossRefGoogle Scholar
  213. Shepherd FA, Giaccone G et al (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20(22):4434–4439PubMedCrossRefGoogle Scholar
  214. Shi W, Siemann DW (2002) Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer 87(1):119–126PubMedCrossRefGoogle Scholar
  215. Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37(1):63–74PubMedCrossRefGoogle Scholar
  216. Siemann DW, Horsman MR (2002) Enhancement of radiation therapy by vascular targeting agents. Curr Opin Investig Drugs 3(11):1660–1665PubMedGoogle Scholar
  217. Siemann DW, Rojiani AM (2002) Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54(5):1512–1517PubMedCrossRefGoogle Scholar
  218. Siemann DW, Shi W (2003) Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13(1):53–61PubMedCrossRefGoogle Scholar
  219. Sin N, Meng L et al (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 94(12):6099–6103PubMedCrossRefGoogle Scholar
  220. Socinski MA, Novello S et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26(4):650–656PubMedCrossRefGoogle Scholar
  221. Socinski MA, Langer CJ et al (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27(31):5255–5261PubMedCrossRefGoogle Scholar
  222. Solorzano CC, Baker CH et al (2001) Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16(5):359–370PubMedCrossRefGoogle Scholar
  223. Spigel DR, Greco FA et al (2009) Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 4(12):1555–1560PubMedCrossRefGoogle Scholar
  224. Spratlin JL, Cohen RB et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28(5):780–787PubMedCrossRefGoogle Scholar
  225. St Croix B, Rago C et al (2000) Genes expressed in human tumor endothelium. Science 289(5482):1197–1202PubMedCrossRefGoogle Scholar
  226. Sternberg CN, Davis ID et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068PubMedCrossRefGoogle Scholar
  227. Steward WP (1999) Marimastat (BB2516): Current status of development. Cancer Chemother Pharmacol 43(Suppl):S56–60PubMedCrossRefGoogle Scholar
  228. Strizzi L, Vianale G et al (2001) Basic fibroblast growth factor in mesothelioma pleural effusions: Correlation with patient survival and angiogenesis. Int J Oncol 18(5):1093–1098PubMedGoogle Scholar
  229. Strobel D, Krodel U et al (2000) Clinical evaluation of contrast-enhanced color Doppler sonography in the differential diagnosis of liver tumors. J Clin Ultrasound 28(1):1–13PubMedCrossRefGoogle Scholar
  230. Swensen SJ, Yamashita K et al (2000) Lung nodules: Dual-kilovolt peak analysis with CT–multicenter study. Radiology 214(1):81–85PubMedGoogle Scholar
  231. Takahashi S, Shinya T et al (2010) Angiostatin inhibition of vascular endothelial growth factor-stimulated nitric oxide production in endothelial cells. J Pharmacol Sci 112(4):432–437PubMedCrossRefGoogle Scholar
  232. Takase Y, Kai K et al (2010) Endoglin (CD105) expression and angiogenesis status in small-cell lung cancer. Pathol Res Pract 206(11):725–730PubMedCrossRefGoogle Scholar
  233. Takigawa N, Segawa Y et al (1998) Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 18(2B):1251–1254PubMedGoogle Scholar
  234. Tamura M, Ohta Y et al (2001) Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small-cell lung cancer. Oncol Rep 8(5):1097–1102PubMedGoogle Scholar
  235. Tamura M, Ohta Y et al (2002) Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small-cell lung cancer. Int J Biol Markers 17(4):275–279PubMedGoogle Scholar
  236. Tanigawa N, Amaya H et al (1996) Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 56(11):2671–2676PubMedGoogle Scholar
  237. Tateishi U, Kusumoto M et al (2002) Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer 95(4):835–842PubMedCrossRefGoogle Scholar
  238. Teng LS, Jin KT et al (2010) Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 73(9):449–456PubMedCrossRefGoogle Scholar
  239. Thomas JP, Arzoomanian RZ et al (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21(2):223–231PubMedCrossRefGoogle Scholar
  240. Toi M, Kashitani J et al (1993) Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55(3):371–374PubMedCrossRefGoogle Scholar
  241. Trepel M, Grifman M et al (2000) Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum Gene Ther 11(14):1971–1981PubMedCrossRefGoogle Scholar
  242. Trivella M, Pezzella F et al (2007) Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 8(6):488–499PubMedCrossRefGoogle Scholar
  243. Tuder RM, Cool CD et al (2001) The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 22(3):405–418PubMedCrossRefGoogle Scholar
  244. Ucuzian AA, Gassman AA et al (2010) Molecular mediators of angiogenesis. J Burn Care Res 31(1):158–175PubMedCrossRefGoogle Scholar
  245. Ueno K, Inoue Y et al (2001) Increased serum levels of basic fibroblast growth factor in lung cancer patients: Relevance to response of therapy and prognosis. Lung Cancer 31(2–3):213–219PubMedCrossRefGoogle Scholar
  246. van der Woude HJ, Bloem JL et al (1995) Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response. Am J Roentgenol 165(1):125–133CrossRefGoogle Scholar
  247. Varallyay CG, Muldoon LL et al (2009) Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 29(4):853–860PubMedCrossRefGoogle Scholar
  248. Veenendaal LM, Jin H et al (2002) In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 99(12):7866–7871PubMedCrossRefGoogle Scholar
  249. Vermeulen PB, Gasparini G et al (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A(14):2474–2484PubMedCrossRefGoogle Scholar
  250. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99(2):157–166PubMedCrossRefGoogle Scholar
  251. Volm M, Koomagi R et al (1997) Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small-cell lung carcinomas. Eur J Cancer 33(4):691–693PubMedCrossRefGoogle Scholar
  252. Watanabe Y, Dvorak HF (1997) Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. Exp Cell Res 233(2):340–349PubMedCrossRefGoogle Scholar
  253. Webb NJ, Bottomley MJ et al (1998) Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94(4):395–404Google Scholar
  254. Wedam SB, Low JA et al (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24(5):769–777PubMedCrossRefGoogle Scholar
  255. Wedge SR, Kendrew J et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65(10):4389–4400PubMedCrossRefGoogle Scholar
  256. Weidner N, Carroll PR et al (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143(2):401–409PubMedGoogle Scholar
  257. Weir HK, Thun MJ et al (2003) Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95(17):1276–1299PubMedCrossRefGoogle Scholar
  258. Werb Z, Vu TH et al (1999) Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107(1):11–18PubMedCrossRefGoogle Scholar
  259. WHO (1979) WHO handbook for reporting results of cancer treatment. World Health Organization. Geneva, SwitzerlandGoogle Scholar
  260. Willett CG, Duda DG et al (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27(18):3020–3026PubMedCrossRefGoogle Scholar
  261. Witte L, Hicklin DJ et al (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17(2):155–161PubMedCrossRefGoogle Scholar
  262. Wu XH, Qian C et al (2011) Correlations of hypoxia-inducible factor-1alpha/hypoxia-inducible factor-2alpha expression with angiogenesis factors expression and prognosis in non-small-cell lung cancer. Chin Med J (Engl) 124(1):11–18Google Scholar
  263. Yamashita J, Ogawa M et al (1999) Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small-cell lung cancer. Chest 116(1):206–211PubMedCrossRefGoogle Scholar
  264. Yamazaki K, Abe S et al (1994) Tumor angiogenesis in human lung adenocarcinoma. Cancer 74(8):2245–2250PubMedCrossRefGoogle Scholar
  265. Yang DX, Li NE et al (2010) Expression of Elf-1 and survivin in non-small cell lung cancer and their relationship to intratumoral microvessel density. Chin J Cancer 29(4):396–402PubMedCrossRefGoogle Scholar
  266. Yi CA, Lee KS et al (2004) Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233(1):191–199PubMedCrossRefGoogle Scholar
  267. Zahiragic L, Schliemann C et al (2007) Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 21(6):1310–1312PubMedCrossRefGoogle Scholar
  268. Zhang W, D S, Yang D et al (2009) Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 27:8032CrossRefGoogle Scholar
  269. Zhou ZT, Zhou FX et al (2011) Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell-lung cancer. Cancer Chemother Pharmacol (Epub ahead of print)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Department of Radiation OncologyThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Department of Radiation OncologyShands Cancer Center, University of FloridaGainesvilleUSA

Personalised recommendations